HEALTH TECHNOLOGY

MedNetOne Health Solutions Is the First Physician Organization in Michigan to Have a Joint Venture with Honest Medical Group

Honest Medical Group | June 13, 2022

MedNetOne Health

MedNetOne Health Solutions announced it is the first Michigan physician organization to enter into a joint venture with Nashville-based Honest Medical Group, a physician enablement company aimed at improving the health care experience and reducing costs for members with Medicare Advantage.

The announcement was made by MedNetOne co-founders Ewa Matuszewski, CEO, and Al Juocys, D.O., President and Chief Medical Officer. It follows Blue Cross Blue Shield of Michigan's announcement that it would form a joint venture with Honest Medical Group to facilitate independent joint ventures between physician groups such as MedNetOne and Honest Medical Group for risk and revenue sharing.

"This is a huge step in the right direction for Medicare Advantage providers and their patients. Transforming primary care is no longer a dream – it's a reality. And we could not be more excited about where the partnership will take us for the benefit of patients."

Dr. Aric Coffman, CEO of Honest Medical Group

MedNetOne has been tightly connected with payors focusing on innovative, patient-centered quality care programs and its capacity to meet quality performance measures reliably. This emphasis encouraged the company to seek a partnership with the Honest Medical Group earnestly.

MedNetOne provides a wide range of services to independent medical practices, advanced practice physicians, mental health specialists, and chiropractors that are intent on running fully integrated, population-based, patient-centric practices with modern technological infrastructure. In addition, 18% of the population served is at least 65 years old and qualified for or enrolled in a Medicare Advantage plan.

The company tests, develops, and implements novel care management techniques and expanded multidisciplinary team care services, emphasizing providing care for the complete person to people with chronic illnesses such as diabetes, hypertension, obesity, chronic pain, and asthma. Additionally, the company has expanded its offerings to include palliative care.

During the pandemic, MedNetOne established 120 vaccination clinics in schools and ethnic areas and is a partner of the Detroit Equity Coalition on Covid-19.

The organization has recently launched a mobile clinic for community-based treatment, particularly in marginalized regions, to provide primary care services such as chronic illness care, physicals, blood pressure screenings, and immunizations.
 

Spotlight

AHI Enrollment Specialist Tina Trombly explains Child Health Plus, an affordable health insurance plan with no co-pays or deductibles for New York State children birth to age 19.

Spotlight

AHI Enrollment Specialist Tina Trombly explains Child Health Plus, an affordable health insurance plan with no co-pays or deductibles for New York State children birth to age 19.

Related News

HEALTH TECHNOLOGY

MobileSmith Health Announces Go-Live at CHI St. Vincent Infirmary

MobileSmith | September 15, 2022

MobileSmith a leading provider of cutting-edge mobile software solutions, announces delivery and live status of their PeriOp solution at CHI St. Vincent Infirmary. MobileSmith Health is proud to partner with CHI St. Vincent in improving throughput and clinical care for surgical patients using the PeriOp solution. This toolset provides visibility of patient activities and status to the clinical team preparing to welcome patients for surgery. The adherence dashboard helps clinicians focus on the patients who need the most help. Patients, in turn, get education about their procedure, complete necessary preoperative tasks, and are better prepared to manage their care at home. "We are thrilled to partner with CHI St. Vincent and their innovative team. Our work addresses patient outcomes while improving patient satisfaction. It also reduces the workload of clinical staff by automating routine tasks and improving predictability in patient throughput," Chris Caramanico, Chief Executive Officer of MobileSmith Health "The MobileSmith Health team has been a pleasure to work with. We have a shared vision and passion to make healthcare communication to the patient reliable and more efficient. The combination of MobileSmith Health and our talented and innovative team at CHI St. Vincent are proving that we can make a difference in the daily work of many clinicians while improving patient outcomes," said Dr. Jill Flaxman, Medical Director of Perioperative Services. About MobileSmith MobileSmith Health is a digital health technology company focused on increasing efficiency and improving outcomes by providing clinicians with modern pre- and post-surgery dashboard, showing how patients participate in their own care. PeriOp, MobileSmith Health’s patient app, connects providers to their patients, streamlines information, simplifies surgery preparation and discharge and reduces complications. PeriOp by MobileSmith Health makes the science, process and oversight simple.

Read More

FUTURE OF HEALTHCARE

Quipt Home Medical Announces Supply Contract with Cardinal Health Further Expanding Continuum of Care

Quipt Home Medical Corp | July 26, 2022

Quipt Home Medical Corp. a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, is very pleased to announce the execution of a contract with Cardinal Health at-Home, a business unit of Cardinal Health, Inc. wherein Quipt has agreed to offer to sell, and Cardinal has agreed to supply and distribute, disposable medical supplies nationwide. Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for healthcare facilities. “The execution of this contract with Cardinal Health for the supply of disposable medical supplies is an important milestone for Quipt, and we are thrilled to form this alliance during a period of significant growth. Cardinal will service our entire operating footprint, consisting of 94 locations across the country aimed at increasing distribution channels while decreasing costs. Furthermore, this contract will provide us the ability to expand our continuum of care, produce meaningful cross selling opportunities and allow us to further leverage the national insurance contract recently announced. This contract with Cardinal will also assist us in expanding our presence in the states we serve giving us additional verticals to go after. Additionally, any new acquisitions, will benefit from being able to immediately leverage the contract at new locations across the country, providing further synergies with the expectation this contract will give us stronger buying power for disposable medical supplies. The contract with Cardinal, recent new national insurance contract, and deep acquisition pipeline have us extremely excited about the remainder of 2022 and beyond.” Greg Crawford, Chairman and CEO of Quipt ABOUT QUIPT HOME MEDICAL CORP. The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient. ABOUT CARDINAL HEALTH Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 30 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Cardinal Health at-Home provides Home Medical Equipment and Home Health and Hospice teams with comprehensive solutions to better support their patients in the home.

Read More

HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution. The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections. The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs. "We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias." Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022 At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study. "These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy." The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

Read More